Adamis Pharmaceuticals Corp (ADMP)

[66Mustang]

Josey, I have heard anecdotally that, particularly with Fentanyl and other modern street narcotics, some patients have an incomplete response to an initial dosing of Naloxone and therefore require a second dose for resuscitation/revival. I have also heard that there is some time interval required to make the assessment of whether or not a second dose is required for a particular patient, and that additional time can be rather critical in determining the outcome.

As an experienced medical professional, have you ever found this to be true in own experience? It seems the intent of the ZIMHI product is to allow for a substantial enough dosing that a second dose should not be required, but without risk of providing the patient with TOO much Naloxone. If your experience includes any instances of a second dosing being required, to me that would certainly help validate the entire reason for the ZIMHI product regardless of the means of administering it (nasal vs. injection).

I appreciate any honest feedback you can provide on this.


Message in reply to:
Needle safety guards are super easy to use, both in an OR or in the back of a moving ambulance. I’ve done both, extensively.

This was the standard for IV catheters for a long time. Then they moved to a
Push-button system- which is safer, but I personally like less as you can accidentally trigger the needle retraction with slightly too much pressure.

So ADMP could easily move to a push button system.

However, I will admit, intranasal admin is drastically easier prehospital.